Microbial Limits Testing¶
Microbiological Quality Control for Peptide Products¶
Introduction¶
Microbiological quality control ensures that peptide products meet pharmacopeial standards for microbial safety. For peptides intended for research, in vivo administration, or clinical use, bioburden and endotoxin testing are mandatory. This page describes the testing framework defined by USP <61> (Enumeration of Microorganisms), USP <62> (Specified Microorganisms), USP <71> (Sterility), and USP <85> (Bacterial Endotoxins). Together, these tests establish whether a peptide product is safe for its intended route of administration.
Lyophilized peptides, aqueous formulations, and bulk drug substances each require a tailored testing strategy. The selection of tests depends on the product's intended use, regulatory classification, and manufacturing environment.
USP <61>: Enumeration of Microbiological Quality¶
USP <61> defines the total aerobic microbial count (TAMC) and total combined yeasts and molds count (TYMC). The membrane filtration method is preferred for peptides that contain preservatives or are difficult to plate directly.
Incubation Conditions¶
| Parameter | TAMC (Bacteria) | TYMC (Yeasts & Molds) |
|---|---|---|
| Medium | Soybean casein digest agar (SCDA) | Sabouraud dextrose agar (SDA) |
| Temperature | 30–35 °C | 20–25 °C |
| Incubation time | 3–5 days | 5–7 days |
| Atmosphere | Aerobic | Aerobic |
| Inoculum method | Pour plate, spread plate, or membrane filtration | Pour plate or membrane filtration |
Test Organisms for Growth Promotion (USP <61>)¶
| Microorganism | Strain | Expected Recovery (CFU) | Purpose |
|---|---|---|---|
| Staphylococcus aureus | ATCC 6538 | Within factor 2 of inoculum | Gram-positive bacteria |
| Pseudomonas aeruginosa | ATCC 9027 | Within factor 2 of inoculum | Gram-negative bacteria |
| Bacillus subtilis | ATCC 6633 | Within factor 2 of inoculum | Spore-forming bacteria |
| Candida albicans | ATCC 10231 | Within factor 2 of inoculum | Yeast |
| Aspergillus brasiliensis | ATCC 16404 | Within factor 2 of inoculum | Mold |
Growth promotion tests are performed with each batch of media and at the time of testing. If any test organism fails to grow within the expected factor of 2 from the inoculum, the media or conditions are invalidated.
USP <62>: Specified Microorganisms¶
USP <62> tests for the absence of objectionable microorganisms. For peptide products, the following specified microorganisms are tested:
| Microorganism | Method | Enrichment | Selective Isolation | Acceptance Criterion |
|---|---|---|---|---|
| Staphylococcus aureus | Enrichment + plating | SCD broth, 30–35 °C, 24–48 h | Mannitol salt agar | Absent in 1 g |
| Pseudomonas aeruginosa | Enrichment + plating | SCD broth, 30–35 °C, 24–48 h | Cetrimide agar | Absent in 1 g |
| Escherichia coli | Enrichment + plating | MacConkey broth (pre-enrichment) | EMB or MacConkey agar | Absent in 1 g |
| Salmonella spp. | Enrichment + plating | Rappaport–Vassiliadis broth | XLD or Hektoen agar | Absent in 10 g |
| Candida albicans | Enrichment + plating | SCD broth, 30–35 °C | Oxytetracycline–gentamicin agar | Absent in 1 g |
Acceptance Criteria for Peptide Products¶
| Application | TAMC (CFU/g) | TYMC (CFU/g) | Specified Pathogens | Endotoxin (EU/mg) | Sterility (USP <71>) |
|---|---|---|---|---|---|
| Research peptide (non-sterile) | ≤1000 | ≤100 | Absent in 1 g | Test not required | Not required |
| In vivo (injectable, GMP) | ≤100 | ≤20 | Absent in 1 g | ≤5.0 EU/mg | Sterile |
| Clinical trial material (GMP) | ≤100 | ≤20 | Absent in 1 g | ≤5.0 EU/mg | Sterile |
| Ophthalmic | ≤100 | ≤20 | Absent in 1 g | ≤0.5 EU/mg | Sterile |
| Topical | ≤1000 | ≤100 | Absent in 1 g | Not applicable | Not required (typically) |
Bioburden Sampling Plan¶
| Batch Size (units) | Minimum Samples | Sampling Points |
|---|---|---|
| <100 | 5 | Start, middle, end of fill |
| 100–500 | 10 | Systematic (every Nth unit) |
| >500 | 20 | Stratified across fill run |
For lyophilized peptides, samples are reconstituted in sterile water for injection (WFI) prior to membrane filtration. The entire content of a vial is used as the test sample.
Interpretation Guide¶
A failing TAMC or TYMC result typically indicates a contamination event during lyophilization, filling, or packaging. An investigation should include: - Environmental monitoring data (air, surfaces, personnel) - Raw material certificate of analysis review - Verification of media and method (growth promotion, neutralization) - Repeat testing with a fresh sample
For specified microorganism detection, any positive result for S. aureus, P. aeruginosa, or E. coli in a 1 g sample triggers batch rejection. For Salmonella, detection in 10 g is a critical failure.
Common Issues¶
- Sample insolubility: Lyophilized peptides may not fully dissolve. Use a suitable sterile solvent (e.g., DMSO, dilute acetic acid) that does not inhibit microbial growth.
- Antimicrobial carryover: Peptides with inherent antimicrobial activity require membrane filtration to remove the active substance before incubation.
- False positives from handling: All manipulations must be performed in a laminar airflow cabinet with appropriate aseptic technique.
🔗 Related: Endotoxin Testing | Quality Control Overview | Peptide Quality Control Guide | Custom Peptide Synthesis OEM Manufacturing Quality Standards